Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  AbbVie Inc    ABBV

ABBVIE INC (ABBV)

Delayed Quote. Delayed  - 09/23 10:00:24 pm
64.98 USD   -0.15%
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- 2nd Upd..
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
09/19/2016 09/20/2016 09/21/2016 09/22/2016 09/23/2016 Date
62.91(c) 63.28(c) 64.1(c) 65.08(c) 64.98(c) Last
7 903 516 4 826 460 7 587 358 5 416 092 5 154 154 Volume
-0.57% +0.59% +1.30% +1.53% -0.15% Change
More quotes
Financials ($)
Sales 2016 25 807 M
EBIT 2016 10 736 M
Net income 2016 6 202 M
Debt 2016 26 167 M
Yield 2016 3,50%
Sales 2017 28 391 M
EBIT 2017 12 453 M
Net income 2017 7 794 M
Debt 2017 24 950 M
Yield 2017 3,84%
P/E ratio 2016 16,74
P/E ratio 2017 12,76
EV / Sales2016 5,11x
EV / Sales2017 4,61x
Capitalization 105 823 M
More Financials
Company
AbbVie, Inc. is a research-based biopharmaceutical company.It engages in the discovery, development, manufacture and sale of a broad line of proprietary pharmaceutical products.The company's focused on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and... 
Sector
Pharmaceuticals
Calendar
10/12Ex-dividend day
More about the company
Surperformance© ratings of AbbVie Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on ABBVIE INC
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- 2nd Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira
09/21 ABBVIE : Researchers say there are no benefits of testosterone treatments for me..
09/20 DR REDDY LABORATORIES : Launches generic paricalcitol injection in us
09/20 Dr. Reddy's Laboratories announces the launch of Paricalcitol Injection in th..
09/20 ABBVIE : BioArctic enters into Collaboration with AbbVie for Parkinson's Disease..
09/19 ABBVIE : Nippon Life Insurance Co Lowers stake in AbbVie Inc (ABBV)
09/16 BIOGEN : AbbVie -New Data Presented At ECTRIMS Reinforce Efficacy of ZINBRYTA (d..
09/15 ABBVIE : New Data Presented at ECTRIMS Reinforce Efficacy of ZINBRYTA™ (Da..
More news
Sector news : Specialty & Advanced Pharmaceuticals
09/23 Endo International CEO steps down, Campanelli named successor
09/23DJSHIRE : Files 8K - Direct Or Off-Balance Sheet Financial Obligation
09/23DJSHIRE : Files 8K - Other Events
09/23DJSHIRE : Files 8K - Entry Into Definitive Agreement
09/23DJMERCK : Keytruda Finds Fast Entry Into China Via Medical-Tourism Push
More sector news : Specialty & Advanced Pharmaceuticals
4-Traders Strategies on ABBVIE INC 
2015A likely recovery
More Strategies
News from SeekingAlpha
09/23 FDA OKs Amgen's Humira biosimilar
09/23 Priority Review Vouchers Revisited
09/23 FDA approval of Amgen's Humira biosimilar expected today
09/23 AbbVie's Viekirax + Exviera shows 98% cure rate in eight weeks in late-stage ..
09/21 Vanquish The Political Fears By Purchasing The I-Shares Biotech ETF
Advertisement
Chart ABBVIE INC
Duration : Period :
AbbVie Inc Technical Analysis Chart | ABBV | US00287Y1091 | 4-Traders
Full-screen chart
Technical analysis trends ABBVIE INC
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 71,3 $
Spread / Average Target 9,7%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Richard A. Gonzalez Chairman & Chief Executive Officer
Azita Saleki-Gerhardt Senior Vice President-Operations
William J. Chase Chief Financial Officer & Executive Vice President
Michael E. Severino Chief Scientific Officer & Executive VP
Robert J. Alpern Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ABBVIE INC9.69%105 823
BIOGEN INC2.03%68 493
MERCK KGAA9.29%14 203
KYOWA HAKKO KIRIN CO L..-14.44%9 295
MALLINCKRODT PLC2.25%8 220
JAZZ PHARMACEUTICALS P..-9.51%7 699
More Results